Currently, there are 45.02M common shares owned by the public and among those 36.31M shares have been available to trade.
The company’s stock has a 5-day price change of -9.72% and -34.75% over the past three months. APGE shares are trading -18.19% year to date (YTD), with the 12-month market performance up to 17.28% higher. It has a 12-month low price of $30.98 and touched a high of $72.29 over the same period. APGE has an average intraday trading volume of 482.35K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -17.15%, -21.90%, and -23.91% respectively.
Institutional ownership of Apogee Therapeutics Inc (NASDAQ: APGE) shares accounts for 80.63% of the company’s 45.02M shares outstanding.
It has a market capitalization of $2.17B and a beta (3y monthly) value of 2.35. The earnings-per-share (ttm) stands at -$2.73. Price movements for the stock have been influenced by the stock’s volatility, which stands at 6.94% over the week and 6.83% over the month.
Analysts forecast that Apogee Therapeutics Inc (APGE) will achieve an EPS of -1.07 for the current quarter, -1.1 for the next quarter and -4.06 for current fiscal year. The lowest estimate earnings-per-share for the quarter is -1.28 while analysts give the company a high EPS estimate of -1.28. Comparatively, EPS for the current quarter was -0.32 a year ago. Earnings per share for the fiscal year are expected to increase by 7.87%, and -39.56% over the next financial year.
Looking at the support for the APGE, a number of firms have released research notes about the stock. Canaccord Genuity stated their Buy rating for the stock in a research note on November 25, 2024, with the firm’s price target at $89. BofA Securities coverage for the Apogee Therapeutics Inc (APGE) stock in a research note released on May 10, 2024 offered a Buy rating with a price target of $80. BTIG Research was of a view on December 20, 2023 that the stock is Buy, while Wedbush gave the stock Outperform rating on August 08, 2023, issuing a price target of $40. TD Cowen on their part issued Outperform rating on August 08, 2023.
